Hong Kong warned of surge in inflammatory bowel disease rates
Scientists from the study that was co-led by researchers from Hong Kong and Canada raised the alarm after a projection model estimated that the prevalence of inflammatory bowel disease in the city would rise from 40 cases per 100,000 people in 2014 to 100 in 2034.
'The 150 per cent increase in the total number in terms of prevalence – this is quite scary,' said Professor Ng Siew Chien, associate dean of the Chinese University of Hong Kong's medical school and an expert in gastroenterology who co-led the study.
'We call this probably an explosion.'
Researchers found that the rates were related to economic development and that less developed places, such as Malaysia and mainland China, had lower rates than Hong Kong, although they were also trending upwards.
IBD refers to a group of conditions that cause swelling and inflammation of tissue in the digestive tract, with Crohn's disease and ulcerative colitis being the two most common types.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
33 minutes ago
- South China Morning Post
OASES drives growth in Hong Kong's innovation landscape by guiding tech companies into the city
Hong Kong has long been recognised as a global financial hub, but in recent years, it has also rapidly emerged as an innovation and technology (I&T) centre. The unique combination of world-class research and development (R&D) facilities, government initiatives aimed at developing I&T-related industries, and strategic connectivity to both mainland China and the rest of the world positions the city as an ideal launch pad for companies specialising in fields such as green technology and smart logistics solutions. The Hong Kong government is actively fostering an ecosystem tailored to grow the city's I&T prowess. Last September, the Innovation and Technology Commission introduced a HK$10 billion (US$1.27 billion) funding programme, the New Industrialisation Acceleration Scheme (NIAS), for enterprises in the fields of life and health technology, artificial intelligence (AI) and data science, and advanced manufacturing and new energy technology that plan to set up smart production facilities in the city. Besides funding, Hong Kong's innovation infrastructure continues to expand, with facilities like the Advanced Manufacturing Centre (AMC) at Tseung Kwan O InnoPark offering cutting-edge prototyping and production capabilities. This complements existing I&T hubs, including Cyberport and the Hong Kong Science Park, to collectively reinforce the city's commitment to hi-tech industrialisation. The Office for Attracting Strategic Enterprises (OASES) serves as a cornerstone of Hong Kong's I&T strategy. Established in 2022 following Chief Executive John Lee Ka-chiu's policy address, OASES focuses on attracting promising strategic enterprises from five industries, namely advanced manufacturing and new energy technology, AI and data science, financial technology, life and health technology, and cultural and creative. As of April, the office has successfully attracted 84 strategic enterprises, which are expected to invest HK$50 billion and create over 20,000 jobs in Hong Kong in the next few years. OASES actively engages with these companies before they enter Hong Kong and also offers various types of support during and after their entry. Such support can range from connecting companies with potential clients and partners to help grow their businesses to providing insights on the latest market trends and relevant government policies. Fourteen of these enterprises belong to the advanced manufacturing and new energy technology industry. Among them is Gotion, a company specialising in battery technology for electric vehicles (EVs) and energy storage systems. First established in 2006 in Hefei in eastern China's Anhui province, Gotion has since expanded its operations to eight R&D centres worldwide, including in the United States, Singapore and Japan. It is one of the largest EV battery manufacturers in the world and ranks sixth in the industry in terms of market share.
South China Morning Post
33 minutes ago
- South China Morning Post
Hong Kong doctors get go-ahead to hold hospital, medical school jobs at same time
Hong Kong is allowing doctors to hold positions at both public hospitals and the city's two medical schools under a new 'dual-track' pathway that the government has called a 'breakthrough' in boosting the education and research talent pool. Secretary for Health Lo Chung-mau said on Monday that the mechanism provided a 'more fitting development pathway' for talent to engage in medical, teaching and research work compared with previous arrangements. The framework also provided stronger support for their teaching and research duties, including conferring the title of university professor, he added. 'This arrangement signifies a breakthrough of institutional framework through collaboration between the [Hospital Authority] and the two local medical schools to train and retain medical, teaching and research talent,' Lo said. 'I hope that the dual-track development pathway will enable more doctors who aspire to engage in medical, teaching and research work to realise their ambitions and contribute to Hong Kong's medical innovation and research while providing clinical services to patients.' The new arrangement involves a collaboration between the Health Bureau and Hospital Authority and the two medical schools at the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK).
South China Morning Post
2 hours ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The GSK corporate flag next to a Chinese national flag outside its office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
